NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

NovaBridge BiosciencesNASDAQ: NBP

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit remains negative

Q4 FY2025 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2025
$0+100.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

Mixed currencies · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the highest of 5, against a peer median of -44.5%.
NBP Competitors
Gross Profit for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY+100.0%——
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD———
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%——
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 USD———
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 USD———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$82K USD———
ENGNenGene Holdings Inc.LTM Apr 2026-$369K USD———
AURAAura Biosciences, Inc.LTM Mar 2026-$574K USD-97.3%——
ANNXAnnexon, Inc.LTM Mar 2026-$1.9M USD———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$2.15M USD+8.3%——
ALTAltimmune, Inc.LTM Mar 2026-$14.95M USD-74835.0%—41519.4%
Peer median (excluding NBP) —-44.5%—41519.4%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.